Ana Carolina Giuseppi

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 154 citations · Full text

Hematological Malignancy, Thrombosis, Interim Analysis +12

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

Alì Taher, Maria Domenica Cappellini, Antonis Kattamis et al. · The Lancet Haematology · 2022 · 54 citations

Immunohematology, Transfusion Medicine, Hematology +7

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Aaron T. Gerds, Claire Harrison, Jean‐Jacques Kiladjian et al. · Blood Advances · 2024 · 33 citations · Full text

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

Daniel W. Coyne, H. N. Singh, William T. Smith et al. · Kidney International Reports · 2019 · 32 citations · Full text

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti et al. · Blood · 2020 · 30 citations